
Drais Pharmaceuticals, Inc.: Developing targeted drugs for solid tumor cancer treatment.
Drais Pharmaceuticals, Inc. was founded with the core mission of developing targeted drugs for the treatment of specific medical conditions, particularly solid tumor cancers. The company focuses on creating innovative pharmaceutical solutions designed to improve patient outcomes in oncology. Their primary product is a drug specifically formulated to treat solid tumor cancers, addressing a critical need in the oncology market.
Notable figures affiliated with Drais Pharmaceuticals include experienced professionals in the pharmaceutical and biotech industries, though specific names and investors are not publicly detailed. The company has made significant strides in its field, contributing to advancements in cancer treatment through its specialized drug development. Drais Pharmaceuticals' impact is marked by its commitment to addressing challenging medical conditions and improving therapeutic options for patients with solid tumors.

Dracen Pharmaceuticals
dracenpharma.com

Tigris Pharmaceuticals
tigrispharma.com

Novita Pharmaceuticals
novita-pharm.com

OncoTartis

BioNumerik Pharmaceuticals

CBA Pharma
cbapharma.com

Trio Pharmaceuticals

Terns Pharmaceuticals
ternspharma.com

Bayer Pharmaceuticals
bayer.com

Aria Pharmaceuticals

Rainier Therapeutics

L.E.A.F. Pharmaceuticals

Aktis Oncology
aktisoncology.com

Adventris Pharmaceuticals

Arisaph Pharmaceuticals
Companies similar to Drais Pharmaceuticals include Dracen Pharmaceuticals, Tigris Pharmaceuticals, Novita Pharmaceuticals and OncoTartis.
Drais Pharmaceuticals was founded in 2007.
Drais Pharmaceuticals' headquarters is located in Bridgewater Township, NJ, US.
Drais Pharmaceuticals' most recent funding round was for $13M (USD) in June 2012.
As of Jun 4, 2012, Drais Pharmaceuticals has raised a total of $33M (USD).